CXCL10 and metabolic dysfunction-associated steatotic liver disease: Also, chemokine interferon (IFN)-gamma-inducible protein-10 (IP-10/CXCL10) has been reported to be highly expressed in morbidly obese patients [45] and Chang et al. revealed that IP-10 is an independent risk factor associated with progressive liver injury, insulin resistance, and incident diabetes, indicating this to be a potential biomarker for disease progression and subsequent diabetes and non-alcoholic fatty liver disease (NAFLD) [46].